menu
    • menu
    [{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Elobixibat","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Albireo Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Albireo Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Financing","leadProduct":"Elobixibat","moa":"IBAT","graph1":"Gastroenterology","graph2":"Approved","graph3":"Albireo Pharma","amount2":0.11,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0.11,"dosageForm":"","sponsorNew":"Albireo Pharma \/ Hercules Capital","highestDevelopmentStatusID":"12","companyTruncated":"Albireo Pharma \/ Hercules Capital"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Elobixibat","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Albireo Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Albireo Pharma \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Elobixibat

    Menu

    Elobixibat

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Albireo Pharma

    U.S.A arrow
    ICHH-25
    Not Confirmed

    Albireo Pharma

    U.S.A arrow
    ICHH-25
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Elobixibat

    Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

    Study Phase : Phase II

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Albireo Reports Topline Results from Phase 2 Trial of Elobixibat in NAFLD/NASH

    Details : Following promising results in preclinical studies, the Phase 2 study achieved the primary endpoint of reduction of low-density lipoprotein cholesterol (LDL-C) but did not achieve proof-of-concept for other key NASH measures.

    Product Name : Goofice

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    August 18, 2020

    Lead Product(s) : Elobixibat

    Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

    Highest Development Status : Phase II

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    Albireo Pharma

    U.S.A arrow
    ICHH-25
    Not Confirmed

    Albireo Pharma

    U.S.A arrow
    ICHH-25
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Elobixibat

    Therapeutic Area : Gastroenterology

    Study Phase : Approved

    Sponsor : Hercules Capital

    Deal Size : $105.0 million

    Deal Type : Financing

    DEALS_DEV arrow-down

    Albireo Announces Two Financing Transactions to Extend Cash Runway Into the Beginning of 2022

    Details : These funding arrangements with new and existing partners provide the company additional flexibility and cash runway into the beginning of 2022, past the planned approval and commercial launch of odevixibat for the treatment of progressive familial intra...

    Product Name : Undisclosed

    Product Type : Small molecule

    Upfront Cash : $10.0 million

    June 09, 2020

    Lead Product(s) : Elobixibat

    Therapeutic Area : Gastroenterology

    Highest Development Status : Approved

    Sponsor : Hercules Capital

    Deal Size : $105.0 million

    Deal Type : Financing

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    03

    Albireo Pharma

    U.S.A arrow
    ICHH-25
    Not Confirmed

    Albireo Pharma

    U.S.A arrow
    ICHH-25
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Elobixibat

    Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

    Study Phase : Phase II

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Albireo Completes Enrollment in Phase 2 Study of Elobixibat in NASH/NAFLD

    Details : Trial enrolled 47 patients, and is designed to assess the safety and efficacy of a once-daily 5mg dose of elobixibat over 16 weeks in adult patients across 10 U.S. sites with biopsy-confirmed NASH.

    Product Name : Undisclosed

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    March 10, 2020

    Lead Product(s) : Elobixibat

    Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

    Highest Development Status : Phase II

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth